Abstract Body

Background

Adenoviral vectors have long been utilized in HIV vaccine development to elicit CD8+ T cell responses. However, recent trials have been limited by pre-existing vector immunity, skewed immunodominance hierarchies, and the emergence of viral escape variants. To address these barriers, we developed GRAdHIVNE1, a replication-incompetent gorilla adenovirus serotype 32 (GRAd32) vector encoding a T cell vaccine insert composed of structurally constrained, highly networked HIV epitopes – regions critical to viral fitness and less prone to escape.

Methods

The GRAdHIVNE1 cassette was developed after iterative testing of 12 immunogens, and is comprised of an N-terminal endoplasmic reticulum (ER) insertion signal sequence, 46 networked regions from HIV clade B and C separated by furin cleavage sites, and a universal CD4+ T helper epitope. Immunogenicity was evaluated in BALB/c mice, HLA-A*02:01 and B*07:02 knock-in mice, and New Zealand white rabbits. Animals received a single dose (1×10^8 viral particles), followed by evaluation of antigen-specific CD8+ T cell responses using ELISpot and intracellular cytokine staining for assessments of polyfunctionality.

Results

GRAdHIVNE1 elicited robust, polyfunctional CD8+ T cell responses against two H-2K(d)/D(d)-restricted epitopes in Balb/C mice (Gag AI9 and protease VI9). In HLA-A*02:01 and B*07:02 knock-in mice, vaccination generated strong CD8+ T cell responses to distinct HLA-A*02:01 and B*07:02 restricted networked epitopes derived from key regions of the protease core, reverse transcriptase active site, envelope V1V2 stem, Gag p24 interface and Nef core. Importantly, responses were appropriately MHC/HLA-restricted and polyfunctional, reflecting the capacity of the GRAdHIVNE1 immunogen to process and present epitopes within distinct MHC backgrounds. Preliminary studies in rabbits have further confirmed immunogenicity, supporting cross-species potency.

Conclusions

GRAdHIVNE1 is a newly developed T cell vaccine candidate capable of inducing strong MHC/HLA-restricted CD8+ T cell responses directed against highly networked HIV epitopes in diverse pre-clinical models. These results establish proof-of-concept for the GRAd platform and provide the rationale for human clinical trials currently underway in sub-Saharan Africa (NCT06617091), where novel vaccine strategies remain urgently needed.